Richard Mailman

Professor and College of Medicine Distinguished Senior Scholar

Richard Mailman

Publication Tags

Parkinson Disease Antipsychotic Agents Dopamine Pharmaceutical Preparations Therapeutics Dopamine D2 Receptors Brain Short Term Memory Dopamine Receptors Prefrontal Cortex Hydroxymethylglutaryl Coa Reductase Inhibitors Cholesterol Dopamine Agonists Levodopa Schizophrenia Dihydrexidine Pharmacology Iron Substantia Nigra Odds Ratio Neoplasms Genes Ligands Standard Of Care Cognitive Dysfunction

Most Recent Papers

Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium-dependent, non-D<sub>2</sub> receptor-dependent, manner

Jillian S. Weissenrieder, Jessie L. Reed, George Lucian Moldovan, Martin T. Johnson, Mohamed Trebak, Jeffrey D. Neighbors, Richard B. Mailman, Raymond J. Hohl, 2021, Pharmacology Research and Perspectives

Building a System to Engage and Sustain Research Careers for Physicians.

Xuemei Huang, Sinisa Dovat, Richard B. Mailman, Diane M. Thiboutot, Deborah Berini, Leslie J. Parent, 2021, Academic Medicine on p. 490-494

Nigral MRI features of asymptomatic welders

Eun Young Lee, Michael R. Flynn, Guangwei Du, Mechelle M. Lewis, Michael Goldenberg, Lan Kong, Richard B. Mailman, Young Seoub Hong, Xuemei Huang, 2021, Parkinsonism and Related Disorders on p. 37-43

D<sub>1</sub>, not D<sub>2</sub>, dopamine receptor activation dramatically improves MPTP-induced parkinsonism unresponsive to levodopa

Richard B. Mailman, Yang Yang, Xuemei Huang, 2021, European Journal of Pharmacology

D1 dopamine receptors intrinsic activity and functional selectivity affect working memory in prefrontal cortex

Yang Yang, Sang Min Lee, Fumiaki Imamura, Krishne Gowda, Shantu Amin, Richard B. Mailman, 2021, Molecular Psychiatry on p. 645-655

Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline

Feng Han, Gregory L. Brown, Yalin Zhu, Aaron E. Belkin-Rosen, Mechelle M. Lewis, Guangwei Du, Yameng Gu, Paul J. Eslinger, Richard B. Mailman, Xuemei Huang, Xiao Liu, 2021, Movement Disorders

The D<sub>1</sub>/D<sub>5</sub>Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease

Xuemei Huang, Mechelle M. Lewis, Lauren Van Scoy, Sol De Jesus, Paul J. Eslinger, Amy C. Arnold, Amanda J. Miller, Julio Fernandez-Mendoza, Bethany Snyder, William Harrington, Lan Kong, Xi Wang, Dongxiao Sun, Marielle Delnomdedieu, Sridhar Duvvuri, Susan E. Mahoney, David L. Gray, Richard Mailman, 2020, Journal of Parkinson's Disease on p. 1515-1527

Parkinson's Disease-Related Motor and Nonmotor Symptoms in the Lancaster Amish

Michael D.F. Goldenberg, Xuemei Huang, Honglei Chen, Lan Kong, Teodor T. Postolache, John W. Stiller, Katherine A. Ryan, Mary Pavlovich, Toni I. Pollin, Alan R. Shuldiner, Richard B. Mailman, Braxton D. Mitchell, 2020, Neuroepidemiology on p. 392-397

Brain cholesterol metabolism and Parkinson's disease

Xuemei Huang, Nicholas W. Sterling, Guangwei Du, Dongxiao Sun, Christina Stetter, Lan Kong, Yusheng Zhu, Jeffery Neighbors, Mechelle M. Lewis, Honglei Chen, Raymond J. Hohl, Richard B. Mailman, 2019, Movement Disorders on p. 386-395

Cancer and the dopamine D<sub>2</sub> receptor

Jillian S. Weissenrieder, Jeffrey D. Neighbors, Richard B. Mailman, Raymond J. Hohl, 2019, Journal of Pharmacology and Experimental Therapeutics on p. 111-126

Most-Cited Papers

Quantitative susceptibility mapping of the midbrain in Parkinson's disease

Guangwei Du, Tian Liu, Mechelle M. Lewis, Lan Kong, Yi Wang, James Connor, Richard B. Mailman, Xuemei Huang, 2016, Movement Disorders on p. 317-324

Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study

Xuemei Huang, Alvaro Alonso, Xuguang Guo, David M. Umbach, Maya L. Lichtenstein, Christie M. Ballantyne, Richard B. Mailman, Thomas H. Mosley, Honglei Chen, 2015, Movement Disorders on p. 552-559

Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia

Amy F.T. Arnsten, Ragy R. Girgis, David L. Gray, Richard B. Mailman, 2017, Biological Psychiatry on p. 67-77

Dopamine receptor signaling and current and future antipsychotic drugs

Kevin N. Boyd, Richard B. Mailman, 2012, on p. 53-86

Effects of the D<sub>1</sub> dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder

Daniel R. Rosell, Lauren C. Zaluda, Margaret M. McClure, M. Mercedes Perez-Rodriguez, K. Sloan Strike, Deanna M. Barch, Philip D. Harvey, Ragy R. Girgis, Erin A. Hazlett, Richard B. Mailman, Anissa Abi-Dargham, Jeffrey A. Lieberman, Larry J. Siever, 2015, Neuropsychopharmacology on p. 446-453

Transcriptional repression by the BRG1-SWI/SNF complex affects the pluripotency of human embryonic stem cells

Xiaoli Zhang, Bing Li, Wenguo Li, Lijuan Ma, Dongyan Zheng, Leping Li, Weijing Yang, Min Chu, Wei Chen, Richard B. Mailman, Jun Zhu, Guoping Fan, Trevor K. Archer, Yuan Wang, 2014, Stem Cell Reports on p. 460-474

Projection of the prevalence of Parkinson's disease in the coming decades

Alexander Rossi, Kristin Berger, Honglei Chen, Douglas Leslie, Richard Mailman, Xuemei Huang, 2018, Movement Disorders on p. 156-159

Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor

Michelle G. Baladi, Michael J. Forster, Michael B. Gatch, Richard Mailman, Danielle L. Hyman, Lawrence P. Carter, Aaron Janowsky, 2018, Journal of Pharmacology and Experimental Therapeutics on p. 367-376

Higher iron in the red nucleus marks Parkinson's dyskinesia

Mechelle Lewis, Guangwei Du, Michal Kidacki, Nisargkumar Patel, Michele L. Shaffer, Richard Mailman, Xuemei Huang, 2013, Neurobiology of Aging on p. 1497-1503

Statins may facilitate Parkinson's disease

Guodong Liu, Nicholas W. Sterling, Lan Kong, Mechelle M. Lewis, Richard B. Mailman, Honglei Chen, Douglas Leslie, Xuemei Huang, 2017, Movement Disorders on p. 913-917